Regions: Europe, Middle East, Africa

Arnstein Arnebergsvei 30
1366 Lysaker
Norway
+47 40 00 42 79

E-mail: mail@calpro.no

Regions: North America, Central and South America, Southeast Asia, Asia

10650 Scripps Ranch Blvd., Suite 105
San Diego, CA 92131
United States
+1 858 578 7660
+1 858 578 7447 Fax

E-mail: mail@calpro.no
E-mail: jfewster@calpro.no
E-mail: adminusa@calpro.no

Click here to read more

Li XG, Lv YM, Gu F, Yang XL., Department of Gastroenterology, Peking University Third Hospital, Beijing 100083, China, reported in Beijing Da Xue Xue Bao. 2006 Jun 18;38(3):310-3, that fecal calprotectin as a non-invasive screening biomarker in the differential diagnosis of IBS and symptomatic chronic large intestinal organic disease was better than FOBT, ESR and CRP. It was simple, inexpensive, repeatable and no-invasive. It can be used as a biomarker in exclusion from related organic diseases before the diagnosis of irritable bowel syndrome. PMID: 16778979

Kaner D, Bernimoulin JP, Kleber BM, Heizmann WR, Friedmann A., Department of Periodontology and Synoptic Dentistry, Charite- Universitatsmedizin Berlin, Germany. dogan.kaner@charite.de, reported in J Periodontal Res. 2006 Apr;41(2):132-9 that calprotectin levels in gingival crevicular fluid and their changes reflect periodontal inflammation as well as the clinical treatment outcome. PMID: 16499716

Konikoff MR, Denson LA, Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, concluded in their review in Inflamm Bowel Dis. 2006 Jun;12(6):524-34, that fecal calprotectin correlates well with histological inflammation as detected by colonoscopy with biopsies and has been shown successfully to predict relapses and detect pouchitis in patients with IBD.

Orlando A, Modesto I, Castiglione F, Scala L, Scimeca D, Rispo A, Teresi S, Mocciaro F, Criscuoli V, Marrone C, Platania P, De Falco T, Maisano S, Nicoli N, Cottone M., Department of Internal Medicine, V Cervello Hospital, Palermo, Italy, reported in Eur Rev Med Pharmacol Sci. 2006 Jan-Feb;10(1):17-22, that faecal calprotectin at a dosage > 200 mg/L seems to have a better sensitivity than ultrasound. Values of calprotectin > 200 mg can be an indication to colonoscopy in the group of patients with negative ultrasound in order to detect early recurrence. PMID: 16494106

Bremner A, Roked S, Robinson R, Phillips I, Beattie M. Southampton General Hospital, Southampton, United Kingdom, published data in Acta Paediatr. 2005 Dec;94(12):1855-8, showing that raised faecal calprotectin should prompt further assessment in children with chronic intestinal symptoms, since an organic bowel disorder is likely. PMID: 16421055

The PhiCal Test has now been approved by the FDA for clinical use in the USA

Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Download article here!

Conclusions in recently published editorials and Reviews

The PhiCal Test is very promising for differentiating between functional abdominal pain and IBD in school-aged children. Since the test is simple and non-invasive, many endoscopies can be avoided; this is of special importance in children in whom general anaesthesia will be necessary.